cendakimab (CC-93538) - AbbVie, BMS
lirentelimab (AK002) - Allakos
Cinqair (reslizumab) - Merck (MSD), UCB, Teva
Nucala (mepolizumab) - GSK
Fasenra (benralizumab) - AstraZeneca
etrasimod (APD334) - Pfizer
Dupixent (dupilumab) - Sanofi, Regeneron
http://www.ncbi.nlm.nih.gov/pubmed/36840634
 
Feb 25, 2023
 
Prev Next